SABS — SAB Biotherapeutics Balance Sheet
0.000.00%
- $26.13m
- $23.77m
- $1.32m
Annual balance sheet for SAB Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12.6 | 33.2 | 15 | 56.6 | 20.8 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 20.6 | 8.01 | 5.56 | 0 | 0.055 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 34.5 | 50.2 | 22.1 | 58.9 | 23.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 22.1 | 30.9 | 28.3 | 24.7 | 19.9 |
| Other Long Term Assets | |||||
| Total Assets | 56.5 | 81.1 | 50.9 | 83.9 | 44.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.1 | 26.5 | 15 | 10.8 | 7.98 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 17.5 | 42.6 | 19.8 | 26.6 | 18.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 39 | 38.5 | 31.1 | 57.3 | 26 |
| Total Liabilities & Shareholders' Equity | 56.5 | 81.1 | 50.9 | 83.9 | 44.2 |
| Total Common Shares Outstanding |